HAMBURG, Germany, Jan. 20, 2011 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) today announced that it has entered into a collaboration with Takeda Cambridge Limited, to identify small molecule modulators against GPCR and Protease targets involved in various CNS and Metabolic diseases.
